Merck's Keytruda fails triple negative breast cancer pivotal study
Months after the FDA sanctioned the approval of Roche’s runner up checkpoint inhibitor Tecentriq in combination with Celgene’s Abraxane for treatment naive patients with triple negative breast cancer, Merck’s keynote PD-1 Keytruda has stumbled in a late-stage trial as the second or third line of defense against the rare, aggressive form of cancer.
Patients in the 622-patient trial were either given the blockbuster treatment or chemotherapy. The main goal of the study — overall survival — was not met, Merck said, adding that details will be disclosed at a later date.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters